ContraFect
ContraFect is a biopharmaceutical company based in Yonkers, New York, focused on developing novel therapies for life-threatening infections.
Last updated September 28, 2026
AI crawler reads
No AI crawler has read this profile since Oct 28, 2026.
Overview
ContraFect is a commercial-stage biopharmaceutical company headquartered in Yonkers, New York, in the United States. The company is engaged in the discovery and development of novel biological products and small molecules for the treatment of life-threatening infections, particularly those caused by drug-resistant bacteria. Its pipeline has historically included candidates such as exebacase (CF-301), a lysin enzyme for Staphylococcus aureus bacteremia, and CF-302, among others. ContraFect has pursued clinical trials for its lead programs and has faced the typical risks of clinical-stage biotechnology, including regulatory hurdles and financing needs. The company is publicly traded in the United States, though specific listing details are not provided in the available evidence. Its operations are centered in Yonkers, New York, and its primary market is the United States, with potential global applications for its anti-infective therapies. The official website is contrafect.com, which serves as a corporate information portal. As a biopharmaceutical firm, ContraFect's activities are subject to FDA regulations and the broader dynamics of the pharmaceutical industry, including competition from other antibiotic developers and the urgent public health need for new antimicrobials.
History
ContraFect is a biopharmaceutical company based in Yonkers, New York, United States. It was founded to address the growing threat of antibiotic-resistant infections through innovative biological therapies. The company's research has focused on bacteriophage-derived lysins, a class of enzymes that can rapidly kill bacteria, including drug-resistant strains. Its lead product candidate, exebacase (CF-301), has been evaluated in clinical trials for the treatment of Staphylococcus aureus bacteremia, including methicillin-resistant S. aureus (MRSA). ContraFect has also advanced other programs, such as CF-302, targeting different bacterial pathogens. As a clinical-stage company, ContraFect has relied on financing from public markets and private investors to fund its research and development. The company has faced challenges common to antibiotic development, including scientific, regulatory, and economic hurdles. Its headquarters in Yonkers, New York, places it within the broader New York metropolitan area biotech ecosystem. The official website, contrafect.com, provides corporate and pipeline information. Specific details about its founding year, founders, and current listing status are not available in the provided evidence, but the company is known to be a publicly traded entity in the United States.
Products and positioning
Clinical-stage biopharmaceutical company developing novel anti-infective therapies for drug-resistant infections.
Exebacase (CF-301)
A novel lysin enzyme being developed for the treatment of Staphylococcus aureus bacteremia, including MRSA.
CF-302
An anti-infective candidate targeting bacterial infections.
Recent events
ContraFect reports second-quarter 2020 results[4]
Reported:
ContraFect announced its financial results for the second quarter ended June 30, 2020, including a net loss of $17.6 million.
ContraFect appoints Jane E. Ambler as vice president of clinical microbiology[5]
Reported:
ContraFect announced that Jane E. Ambler, Ph.D. was appointed vice president of clinical microbiology.
Sources5 sources
Cite this profile: Cite the canonical profile. /brand-wiki/contrafect-united-states · Editorial policy · How profiles are compiled